

**From:** [Kandice Martin](#)  
**To:** [AGO - High Cost Prescription Drugs](#)  
**Cc:** [Annie Praino](#); [SPTR.SAGENT](#); [W. Shawn Parker](#); [Rick Peterman](#)  
**Subject:** Vermont Notice of New Drug Introduction Pursuant to 18 V.S.A § 4637(b)  
**Date:** Friday, April 26, 2024 8:46:35 AM  
**Attachments:** [image001.jpg](#)  
[image002.png](#)  
[image003.png](#)  
[image004.png](#)  
[image005.png](#)

---

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

To the Office of the Attorney General:

Pursuant to 18 V.S.A § 4637(c), Sagent Pharmaceuticals provides the following report for Lincomycin Injection.

NDC	Product Name	Product Description
25021-0193-10	Lincomycin Injection	Lincomycin Injection (300mg/ml, 10ml, 10x10ml)

Marketing and Pricing Plans

No amount spent on Marketing.

Estimated Patient Volume

1800

Breakthrough Therapy/Priority Review

No

Product introduction date

9/26/2023

-  
Wholesale Acquisition Cost (WAC) per package

\$950.20

-  
Acquisition Date and Price

N/a

Please reach out if you have any questions.

Regards,

**Kandice Martin** | *Senior Commercial Analyst*

M: + (862) 406-8550 | E: [Kandice.Martin@rldatixlifesciences.com](mailto:Kandice.Martin@rldatixlifesciences.com)

